-
Reproductive Sciences (Thousand Oaks,... Feb 2024Endometriosis is an immune chronic inflammatory disease, and there are currently no more effective drugs for treating endometriosis due to its unknown etiology....
Endometriosis is an immune chronic inflammatory disease, and there are currently no more effective drugs for treating endometriosis due to its unknown etiology. Salbutamol is a β2-adrenergic receptor (β2AR) agonist commonly used to treat asthma by selectively activating β2 receptors on airway smooth muscle and leukocytes, exerting bronchial dilation and synergistic anti-inflammatory effects. In recent years, β2AR agonists have been used in endometriosis studies, and we speculate that salbutamol may have a therapeutic effect on endometriosis. The purpose of this research was to explore the therapeutic effect of salbutamol on endometriosis mice. The mouse endometriosis model was established and treated with different doses of salbutamol. Endometrial lesions were harvested for pathological diagnosis, immunohistochemistry (IHC), Masson staining, and toluidine blue analysis. We found that the number and size of endometriotic lesions were all significantly decreased after 3 weeks of treatment with different doses of salbutamol on endometriosis model mice (P < 0.05). After Salbutamol treatment, the amount of mast cells (toluidine blue) and macrophages (F4/80) in the lesions as well as the expressions of interleukin (IL)-1β, tumor necrosis factor (TNF)-ɑ, platelet-derived growth factor subunit B (PDGFB), CD31, transforming growth factor (TGF)-β, Masson staining, BCL2, TUBB3, substance P (SP), and nerve growth factor (NGF) were significantly reduced (P < 0.05). These results suggested that salbutamol could effectively treat endometriosis in mice by reducing immune inflammatory cells and factors, angiogenesis, and fibrosis, increasing apoptosis of endometriotic lesions, and decreasing neurogenesis.
Topics: Humans; Female; Mice; Animals; Endometriosis; Albuterol; Tolonium Chloride; Substance P
PubMed: 37814201
DOI: 10.1007/s43032-023-01371-0 -
Indian Journal of Cancer 2023Diagnostic adjuncts such as toluidine blue have been investigated as screening tools that improve visual examination of potentially malignant disorders (PMD) and oral...
BACKGROUND
Diagnostic adjuncts such as toluidine blue have been investigated as screening tools that improve visual examination of potentially malignant disorders (PMD) and oral cancer. Acetic acid has been reported to be of value in the early detection of cervical cancers. This study assessed the utility of 5% acetic acid as a diagnostic adjunct in oral PMD and compared the accuracy of acetic acid with toluidine blue in the detection of dysplastic PMD and high-risk lesions.
MATERIALS AND METHODS
This cross-sectional study was conducted at a dental hospital in a rural setting. Thirty-one patients with oral PMD formed the study group. Five percent acetic acid was applied to the lesions, followed by toluidine blue application and biopsy. Sensitivity, specificity, and positive and negative predictive values were computed considering true positives as stain uptake in dysplastic and high-risk PMD.
RESULTS
The sensitivity, specificity, and positive and negative predictive values of acetic acid for identifying dysplastic or malignant lesions were 100%, 13.3%, 51.2%, and 100%, respectively, and that for toluidine blue were 75%, 100%, 100%, and 78.9%, respectively. The corresponding values for identifying high-risk PMD (lesions with moderate and severe dysplasia) using acetic acid were 100%, 9.1%, 25.9%, and 100%, respectively, and for toluidine blue were 85.7%, 81.8%, 60%, and 94.7%, respectively.
CONCLUSION
The utility of acetic acid in detecting dysplasia and high-risk PMD is severely limited due to its poor specificity. Compared with acetic acid, toluidine blue is a superior screening tool.
Topics: Humans; Tolonium Chloride; Acetic Acid; Cross-Sectional Studies; Precancerous Conditions; Mouth Diseases
PubMed: 36861696
DOI: 10.4103/ijc.IJC_42_21 -
Advanced Science (Weinheim,... Apr 2024Tumors often overexpress glucose-regulated proteins, and agents that interfere with the production or activity of these proteins may represent novel cancer treatments....
Tumors often overexpress glucose-regulated proteins, and agents that interfere with the production or activity of these proteins may represent novel cancer treatments. The chlorpromazine derivative JX57 exhibits promising effects against endometrial cancer with minimal extrapyramidal side effects; however, its mechanisms of action are currently unknown. Here, glucose-regulated protein 75 kD (GRP75) is identified as a direct target of JX57 using activity-based protein profiling and loss-of-function experiments. The findings show that GRP75 is necessary for the biological activity of JX57, as JX57 exhibits moderate anticancer properties in GRP75-deficient cancer cells, both in vitro and in vivo. High GRP75 expression is correlated with poor differentiation and poor survival in patients with endometrial cancer, whereas the knockdown of GRP75 can significantly suppress tumor growth. Mechanistically, the direct binding of JX57 to GRP75 impairs the structure of the mitochondria-associated endoplasmic reticulum membrane and disrupts the endoplasmic reticulum-mitochondrial calcium homeostasis, resulting in a mitochondrial energy crisis and AMP-activated protein kinase activation. Taken together, these findings highlight GRP75 as a potential prognostic biomarker and direct therapeutic target in endometrial cancer and suggest that the chlorpromazine derivative JX57 can potentially be a new therapeutic option for endometrial cancer.
Topics: Female; Humans; AMP-Activated Protein Kinases; Chlorpromazine; Endometrial Neoplasms; HSP70 Heat-Shock Proteins; Membrane Proteins; Mitochondria
PubMed: 38342610
DOI: 10.1002/advs.202304203 -
JAMA Psychiatry Mar 2024Dose-related effects of antipsychotic medications may increase mortality in children and young adults.
IMPORTANCE
Dose-related effects of antipsychotic medications may increase mortality in children and young adults.
OBJECTIVE
To compare mortality for patients aged 5 to 24 years beginning treatment with antipsychotic vs control psychiatric medications.
DESIGN, SETTING, AND PARTICIPANTS
This was a US national retrospective cohort study of Medicaid patients with no severe somatic illness or schizophrenia or related psychoses who initiated study medication treatment. Study data were analyzed from November 2022 to September 2023.
EXPOSURES
Current use of second-generation antipsychotic agents in daily doses of less than or equal to 100-mg chlorpromazine equivalents or greater than 100-mg chlorpromazine equivalents vs that for control medications (α agonists, atomoxetine, antidepressants, and mood stabilizers).
MAIN OUTCOME AND MEASURES
Total mortality, classified by underlying cause of death. Rate differences (RDs) and hazard ratios (HRs) adjusted for potential confounders with propensity score-based overlap weights.
RESULTS
The 2 067 507 patients (mean [SD] age, 13.1 [5.3] years; 1 060 194 male [51.3%]) beginning study medication treatment filled 21 749 825 prescriptions during follow-up with 5 415 054 for antipsychotic doses of 100 mg or less, 2 813 796 for doses greater than 100 mg, and 13 520 975 for control medications. Mortality was not associated with antipsychotic doses of 100 mg or less (RD, 3.3; 95% CI, -5.1 to 11.7 per 100 000 person-years; HR, 1.08; 95% CI, 0.89-1.32) but was associated with doses greater than 100 mg (RD, 22.4; 95% CI, 6.6-38.2; HR, 1.37; 95% CI, 1.11-1.70). For higher doses, antipsychotic treatment was significantly associated with overdose deaths (RD, 8.3; 95% CI, 0-16.6; HR, 1.57; 95% CI, 1.02-2.42) and other unintentional injury deaths (RD, 12.3; 95% CI, 2.4-22.2; HR, 1.57; 95% CI, 1.12-2.22) but was not associated with nonoverdose suicide deaths or cardiovascular/metabolic deaths. Mortality for children aged 5 to 17 years was not significantly associated with either antipsychotic dose, whereas young adults aged 18 to 24 years had increased risk for doses greater than 100 mg (RD, 127.5; 95% CI, 44.8-210.2; HR, 1.68; 95% CI, 1.23-2.29).
CONCLUSIONS AND RELEVANCE
In this cohort study of more than 2 million children and young adults without severe somatic disease or diagnosed psychosis, antipsychotic treatment in doses of 100 mg or less of chlorpromazine equivalents or in children aged 5 to 17 years was not associated with increased risk of death. For doses greater than 100 mg, young adults aged 18 to 24 years had significantly increased risk of death, with 127.5 additional deaths per 100 000 person-years.
Topics: Child; Humans; Male; Young Adult; Adolescent; Antipsychotic Agents; Chlorpromazine; Retrospective Studies; Cohort Studies; Schizophrenia
PubMed: 38019523
DOI: 10.1001/jamapsychiatry.2023.4573 -
Chemosphere Oct 2023Dyestuff wastewater and pharmaceutical wastewater have become typical representatives of water pollution. In this study, a novel nano-silica-biochar composite (NSBC) was...
Dyestuff wastewater and pharmaceutical wastewater have become typical representatives of water pollution. In this study, a novel nano-silica-biochar composite (NSBC) was synthesized based on corn straw as raw material, by a combination of ball milling, pyrolysis and KOH activation. The modified biochar with rough surface had higher specific surface area (117.67-132.82 m/g), developed pore structure (0.12-0.15 cm/g) and abundant surface functional groups (-OH, -COOH, Si-O and aromatic CC were dominated). These provided abundant active sites for the adsorption of pollutants. The adsorption capacities of NSBC for Methylene Blue (MB) and Tetracycline (TC) were both higher than that of other similar products, the maximum adsorption capacity of Langmuir were 247.22 and 86.95 mg/g, respectively. After five adsorption-desorption cycle experiments, the adsorption capacities of NSBC for both were still excellent, reaching 99.30 and 19.87 mg/g, respectively. Due to the different structure and molecular size of MB and TC, the adsorption capacities of NSBC were significantly different, especially the influence of solution pH value. The adsorption mechanisms were comprehensively discussed by FTIR and XPS of the samples before and after adsorption, and combining experimental results of BET and simultaneously, which were manifested as monolayer chemisorption, specifically surface complexation, hydrogen bonding, n-π/π-π conjugation, electrostatic interaction and pore filling.
Topics: Methylene Blue; Silicon Dioxide; Wastewater; Adsorption; Charcoal; Anti-Bacterial Agents; Tetracycline; Water Pollutants, Chemical; Kinetics
PubMed: 37399993
DOI: 10.1016/j.chemosphere.2023.139395 -
Methylene blue as adjunctive therapy in septic shock: correct drug diluent derives optimal efficacy.Critical Care (London, England) Aug 2023
Topics: Humans; Methylene Blue; Shock, Septic; Dental Care; Patients
PubMed: 37644588
DOI: 10.1186/s13054-023-04615-2 -
Biotechnic & Histochemistry : Official... Nov 2024Romanowsky staining was an important methodological breakthrough in diagnostic hematology and cytopathology during the late 19 and early 20 centuries; it has facilitated... (Review)
Review
Romanowsky staining was an important methodological breakthrough in diagnostic hematology and cytopathology during the late 19 and early 20 centuries; it has facilitated for decades the work of biologists, hematologists and pathologists working with blood cells. Despite more than a century of studying Romanowsky staining, no systematic review has been published that explains the chemical processes that produce the "Romanowsky effect" or "Romanowsky-Giemsa effect" (RGE), i.e., a purple coloration arising from the interaction of an azure dye with eosin and not due merely to their simultaneous presence. Our review is an attempt to build a bridge between chemists and biomedical scientists and to summarize the available data on methylene blue (MB) demethylation as well as the related reduction and decomposition of MB to simpler compounds by both light and enzyme systems and microorganisms. To do this, we analyze modern data on the mechanisms of MB demethylation both in the presence of acids and bases and by disproportionation due to the action of light. We also offer an explanation for why the RGE occurs only when azure B, or to a lesser extent, azure A is present by applying experimental and calculated physicochemical parameters including dye-DNA binding constants and electron density distributions in the molecules of these ligands. Finally, we discuss modern techniques for obtaining new varieties of Romanowsky dyes by modifying previously known ones. We hope that our critical literature study will help scientists understand better the chemical and physicochemical processes and mechanisms of cell staining with such dyes.
Topics: Azure Stains; Staining and Labeling; Coloring Agents; Methylene Blue; Eosine Yellowish-(YS)
PubMed: 37929609
DOI: 10.1080/10520295.2023.2273860 -
Sensors (Basel, Switzerland) Nov 2023This paper describes the development of a simple voltammetric biosensor for the stereoselective discrimination of myo-inositol (myo-Ins) and D-chiro-inositol...
This paper describes the development of a simple voltammetric biosensor for the stereoselective discrimination of myo-inositol (myo-Ins) and D-chiro-inositol (D-chiro-Ins) by means of bovine serum albumin (BSA) adsorption onto a multi-walled carbon nanotube (MWCNT) graphite screen-printed electrode (MWCNT-GSPE), previously functionalized by the electropolymerization of methylene blue (MB). After a morphological characterization, the enantioselective biosensor platform was electrochemically characterized after each modification step by differential pulse voltammetry (DPV) and electrochemical impedance spectroscopy (EIS). The results show that the binding affinity between myo-Ins and BSA was higher than that between D-chiro-Ins and BSA, confirming the different interactions exhibited by the novel BSA/MB/MWCNT/GSPE platform towards the two diastereoisomers. The biosensor showed a linear response towards both stereoisomers in the range of 2-100 μM, with LODs of 0.5 and 1 μM for myo-Ins and D-chiro-Ins, respectively. Moreover, a stereoselectivity coefficient α of 1.6 was found, with association constants of 0.90 and 0.79, for the two stereoisomers, respectively. Lastly, the proposed biosensor allowed for the determination of the stereoisomeric composition of myo-/D-chiro-Ins mixtures in commercial pharmaceutical preparations, and thus, it is expected to be successfully applied in the chiral analysis of pharmaceuticals and illicit drugs of forensic interest.
Topics: Inositol; Methylene Blue; Stereoisomerism
PubMed: 38005597
DOI: 10.3390/s23229211 -
The American Journal of Nursing Apr 2024
Topics: Humans; Promethazine
PubMed: 38511703
DOI: 10.1097/01.NAJ.0001010556.28403.79 -
Bioresource Technology Jul 2023Hydrochars are promising sorbents for wastewater treatment. Herein, two acrylate-modified hydrochars (AMHC and AMHC) were obtained by grafting acrylic acid on the...
Hydrochars are promising sorbents for wastewater treatment. Herein, two acrylate-modified hydrochars (AMHC and AMHC) were obtained by grafting acrylic acid on the surface of two hydrochars (MHC and MHC hydrothermally carbonized in water and acidic medium respectively) with free radical polymerization. Characterizations show that MHC is more prone to free radical polymerization than MHC does, and has higher carboxylate content after modification. The adsorption amounts of AMHC over methylene blue (MB) and Pb(II) are much higher than those of AMHC. Pseudo-second-order kinetic and Langmuir isotherm equations well fit the Pb(II) and MB sorption data of AMHC. The Pb(II) adsorptive mechanism is mainly inner-surface complexation accompanied by ion exchange and cation-π interaction. MB adsorption involves ion exchange, electrostatic interaction, H-bonding and π-π interaction. Hence, the one-step modification method of free radical polymerization under alkaline condition has great potential for preparing carboxylate-modified hydrochars to adsorb cationic pollutants.
Topics: Methylene Blue; Lead; Adsorption; Water Pollutants, Chemical; Acrylates; Water; Kinetics; Carboxylic Acids; Hydrogen-Ion Concentration
PubMed: 37080438
DOI: 10.1016/j.biortech.2023.129067